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he prevalence of type 2 diabetes has
increased in recent decades to epi-
demic proportions. About 150 mil-
lion individuals worldwide had type 2
diabetes in 2000, and this number is ex-
pected to increase to 300 million by the
year 2025 (1). Because of the chronic
course of type 2 diabetes and the signiﬁ-
cant morbidity and mortality associated
with the vascular complications of the dis-
ease, type 2 diabetes has become not only a
seriouspublichealththreat,butalsoaheavy
economicburdenonthehealthcaresystem.
The total annual cost of diabetes care in the
U.S. was estimated to be $175 billion in the
year 2007, and this number is expected to
increase further with the increasing inci-
dence of the disease (2).
Recent clinical trials have reported a
reduction in the incidence of type 2 dia-
betes with lifestyle intervention (3,4) and
pharmacotherapy (4,5) in subjects with
IGT. These results suggest that primary
prevention of type 2 diabetes could be an
effective strategy to restrain the epidemic
increase in the disease prevalence and re-
ducetheeconomicburdenitposesonthe
health care system.
Accurate identiﬁcation of subjects at
increased risk for future type 2 diabetes is
essentialforanearlypreventionprogram.
Itminimizesthenumberofsubjectsinthe
intervention program while improving
the efﬁcacy and the cost-effectiveness of
theintervention.Animpairedglucosetol-
erance (IGT) test was introduced in 1979
as an intermediate state in the transition
in glucose homeostasis from normal to
overtdiabetes(6).SubjectswithIGThave
increased risk for future type 2 diabetes
(7). Thus, all previous intervention trials
that have tested the efﬁcacy of prevention
strategies have recruited subjects with
IGT (3–5). Although, in general, subjects
with IGT have an increased risk for future
type 2 diabetes, only about half of IGT
subjects ultimately convert to diabetes
(7). On the other hand, the majority of
subjects who develop type 2 diabetes do
not have IGT at baseline (8). Therefore, if
one relies solely on IGT to identify sub-
jects at risk for future type 2 diabetes, a
large fraction of high-risk individuals
whodonothaveIGTandcouldhaveben-
eﬁted from an intervention program
would be missed.
In this review, we will examine pre-
diction models for future risk of type 2
diabetes and demonstrate that models
based on the pathophysiology of the dis-
ease have greater prediction value for the
future development of type 2 diabetes.
WHO IS AT RISK FOR
FUTURE TYPE 2 DIABETES?—
Subjects with IGT have an increased risk
for future type 2 diabetes, with a conver-
sion rate of 5–10% per year (7). Al-
though, in general, subjects with IGT
have increased risk for future type 2 dia-
betes, only 35–50% of individuals with
IGT convert to type 2 diabetes after
10–20 years of follow-up (7–9).
Prospective epidemiological studies
have reported that subjects with isolated
impaired fasting glucose (IFG) (fasting
plasma glucose [FPG] 100–125 mg/dl
and2-hplasmaglucose140mg/dl)also
have an increased risk for future type 2
diabetes despite having a 2-h plasma glu-
cose concentration in the normal range
(10–13). The future risk for type 2 diabe-
tes in subjects with isolated IFG is similar
tothatofsubjectswithisolatedIGT(5%
per year) (7,10–13). Most importantly,
prospective epidemiological studies have
demonstrated that 40 subjects who de-
velop type 2 diabetes at follow-up have
normal glucose tolerance (NGT) at base-
line (7–13). These observations suggest
that1)thefutureriskfortype2diabetesis
not similar among all subjects in any glu-
cose tolerance category and 2) a group of
subjects with 2-h plasma glucose 140
mg/dl have an increased risk for future
type 2 diabetes. Thus, using IGT for the
predictionoffuturetype2diabeteswould
miss this group of subjects with 2-h
plasmaglucoseconcentrationsinthenor-
mal range (140 mg/dl), yet are at in-
creased risk for type 2 diabetes and could
beneﬁt from an intervention program.
Pathogenesis of type 2 diabetes
Subjects with type 2 diabetes have two
major defects: 1) increased insulin resis-
tance in skeletal muscle and liver and 2)
impaired -cell function (14). Both in-
creased insulin resistance and impaired
-cell function are present long before
overthyperglycemiabecomesevident.In-
creased insulin resistance occurs early in
the natural history of type 2 diabetes but
is compensated by increased -cell secre-
tion of insulin. When -cell failure en-
sues, the hyperinsulinemia no longer can
compensate for the insulin resistance and
glucose homeostasis deteriorates. Ini-
tially, this is manifest as impaired glucose
tolerance (IGT), which eventually
progresses to overt diabetes (14). Most
obese individuals are characterized by
moderate-to-severe insulin resistance.
However, the majority (70%) maintain
NGT throughout life because increased
insulin secretion by a healthy -cell is
able to compensate for the insulin resis-
tance.Thus,insulinresistancealoneisnot
sufﬁcient for the development of type 2
diabetes, and progressive -cell failure is
required for the deterioration in glucose
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Insulin resistance is prerequisite for the
development of type 2 diabetes and be-
comes manifest long before hyperglyce-
mia is evident. Thus, models that
quantitate the severity of insulin resis-
tance would be useful for predicting the
future risk of type 2 diabetes. The eugly-
cemic-hyperinsulinemicclampisthegold
standard for quantitation of whole-body
insulin sensitivity (15). However, this
technique is complicated and difﬁcult to
perform in clinical practice. Elevated fast-
ing insulin levels, which represent the
physiological response to insulin resis-
tance, and insulin resistance indexes de-
rivedfromfastingandplasmaglucoseand
insulin concentrations during the oral
glucose tolerance test (OGTT) have been
used to predict the future risk for type 2
diabetes (16). Subjects with insulin resis-
tance have a cluster of metabolic abnor-
malities known as the insulin resistance
(metabolic) syndrome (17), and a num-
ber of epidemiological studies have re-
ported that the metabolic syndrome is a
signiﬁcant predictor of future type 2
diabetes (18). Linear regression models
comprised of individual metabolic
abnormalities associated with the insulin
resistance syndrome (obesity, IFG/IGT,
hypertension,anddyslipidemia),inaddi-
tiontoageandsex,alsohavebeenusedto
predict the future risk of type 2 diabetes
(19–24). The predictive power of these
multivariate models is comparable to that
of IGT. Furthermore, addition of glucose
tolerance status to the multivariate model
didnotimproveitspredictivepower(19).
Because all metabolic components of the
multivariate model are obtained during
the fasting state, these models have been
proposed to replace the diagnosis of IGT
inidentifyingsubjectsatincreasedriskfor
future type 2 diabetes, thereby obviating
the need to perform an OGTT.
As discussed earlier, insulin-resistant
individualsdeveloptype2diabetesonlyif
-cell failure ensues. Thus, measures of
-cell function might be expected to be a
key predictor for future type 2 diabetes.
Thehyperglycemicclampisthegoldstan-
dardmethodforthemeasurementofboth
ﬁrst- and second-phase insulin secretion
(15). Decreased ﬁrst-phase insulin secre-
tion consistently has been reported to
predict the future development of type 2
diabetes(25–28).However,thehypergly-
cemic clamp is complicated and cannot
easily be performed in clinical practice or
in large-scale epidemiological studies.
Surrogate measures of -cell function
obtainedfromplasmaglucoseandinsulin
concentrations during the OGTT corre-
late well with -cell function measured
with the gold standard hyperglycemic
clampmethodandhavebeenshowntobe
good predictors for the future risk of type
2 diabetes (29,30). A decrease in early-
phase insulin secretion (I0–30/G0–30)
during the OGTT has been shown to be a
strong predictor of the future develop-
ment of type 2 diabetes (16,31–33). Be-
cause of the dynamic interaction between
insulin secretion and insulin resistance
(34), the insulin secretion/insulin resis-
tance index (insulin secretion rate related
to the prevailing level of insulin resis-
tance) (I/G  IR) is a better index of
-cell function. We previously have
shownthatthisindexperformssuperiorly
to other models in predicting the risk of
future type 2 diabetes (35). Furthermore,
addition of the insulin secretion/insulin
resistance index to a multivariate predic-
tion model (the San Antonio Prediction
Model), which is based on measurements
taken during the fasting state (e.g., FPG,
HDL, blood pressure, and waist), signiﬁ-
cantly increased the predictive power of
the model (35). Models based on mea-
surements taken during the fasting state
cannot incorporate any measure of -cell
function (35,36). Thus, measures of
-cellfunctionobtainedfromplasmaglu-
cose and insulin concentration obtained
during post–glucose load have additive
information for the future risk of type 2
diabetes compared with measurements
taking during the fasting state.
Insulin resistance, insulin secretion,
and glucose intolerance
Subjects with IGT have impaired early-
and late-phase insulin secretion and in-
creased insulin resistance in skeletal
muscle (37–41). These metabolic abnor-
malities contribute to the increased risk
for future type 2 diabetes. In contrast,
subjects with IFG have impaired early-
phase(ﬁrst-phase)insulinsecretion(with
normal late-phase insulin secretion) and
increased hepatic insulin resistance (with
normal/near-normal muscle insulin sen-
sitivity)(37–44).Itisnoteworthythatthe
decline in -cell function begins at 2-h
plasma glucose concentrations consid-
ered to be well within the normal range
(140 mg/dl) and continuously declines
as the 2-h plasma glucose rises into the
impairedglucosetolerancerange(45,46).
Thus, subjects with a 2-h plasma glucose
of120–140mg/dlmanifestan40–50%
decrease in -cell function compared
with subjects with 2-h plasma glucose
100 mg/dl, yet both groups are consid-
ered to have “normal” glucose tolerance.
Similarly, the decline in ﬁrst-phase insu-
lin secretion begins with FPG concentra-
tionswellwithinthenormalrange(Fig.1)
(44,47). The impairment in -cell func-
tion associated with the deterioration in
glucose tolerance represents a continuum
and clearly begins at a much earlier stage
than previously appreciated. By the time
the plasma glucose reaches the level of
IGT (2-h plasma glucose 140 mg/dl) or
IFG (FPG 100 mg/dl), 40–50% of
-cell function has been lost (44–47).
Thedecreasein-cellfunctioninsubjects
considered to have “normal” glucose tol-
erancemostlikelycontributestothelarge
number of NGT subjects who convert to
type 2 diabetes in prospective epidemio-
logical studies (8). Therefore, by relying
only on IFG and IGT to identify subjects
at increased risk for future type 2 diabe-
tes, those high-risk NGT subjects would
not be identiﬁed. Thus, more accurate
methods to predict the future risk of type
2 diabetes are required to identify this
group of high-risk “normal” glucose tol-
erant individuals.
Fasting versus postload plasma
glucose and risk of type 2 diabetes
Both the fasting and 2-h plasma glucose
concentration during the OGTT are used
to establish the diagnosis of type 2 diabe-
tes. An increase in FPG concentration in
the nondiabetic range has been shown to
be associated with increased risk for fu-
ture type 2 diabetes (7,8,11). Subjects
Figure 1—Relationship between -cell function
and FPG concentration in subjects with NGT.
Subjects were divided in deciles based on FPG
concentration. Each data point is the mean of 29
subjects. The line is the least-square ﬁt for the
data points and is best described by exponential
decay function [ISIR index  32 exp(0.04FPG)]
andhasacorrelationcoefﬁcientofr0.96(P
0.0001). Conc, concentration; G, glucose; IR, in-
sulin resistance measured with the Matsuda in-
dex; ISR, insulin secretory rate.
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and 2-h PG 140 mg/dl) have a 7.5%
annual relative risk for future type 2 dia-
betes compared with NGT subjects (7).
Moreover, the increase in future risk for
type 2 diabetes associated with the in-
crease in FPG concentration is a contin-
uum and begins at a level below the cut
point for impaired fasting glucose (100
mg/dl) (48). Similarly, an increase in 2-h
plasma glucose concentration in the non-
diabetic range (e.g., in subjects with IGT)
also is associated with increased risk for
type 2 diabetes with greater sensitivity
and lower speciﬁcity compared with the
increase observed with the FPG (7,8,11).
However,asdiscussedabove,bothfasting
and 2-h plasma glucose concentrations
correlate closely with -cell function, the
principal factor responsible for the devel-
opment of type 2 diabetes (35,36). First-
phase insulin secretion and hepatic
insulin sensitivity are important determi-
nants of the initial rate of rise in plasma
glucoseconcentrationafterglucoseinges-
tion (49). The rate of decline in plasma
glucose concentration back toward the
fasting level depends on late-phase insu-
lin secretion and insulin sensitivity in
skeletal muscle (49). Thus, changes in
-cellfunctionandinsulinsensitivitywill
inﬂuence not only the absolute plasma
glucose concentration during the fasting
state and at 2 h after a glucose load, but
also the shape of plasma glucose concen-
tration curve during the OGTT: rate of
plasmaglucoseincrease,peakplasmaglu-
coseconcentration,rateofplasmaglucose
decrease, and the time required for the
plasma glucose concentration to return
tothefastinglevel(50).Thus,theshapeof
the plasma glucose concentration during
the OGTT provides a surrogate measure
of-cellfunctionandwhole-bodyinsulin
resistance and is a good predictor of the
future risk of type 2 diabetes, above and
beyond the fasting and 2-h plasma glu-
cose concentration (50). Consistent with
this concept, we have shown that the in-




2 diabetes, independent of the glucose
tolerance status (35,36). Addition of
G(0–120) to prediction models based on
measurements taken during the fasting
state signiﬁcantly improves their predic-
tive power (35,36).
The time it takes for plasma glucose
concentration to return to or below the
FPG concentration during the OGTT also
is an important predictor for the future
development of type 2 diabetes. Normal
glucose tolerant subjects who return their
plasma glucose concentration back to the
fastinglevelin60minduringtheOGTT
have a signiﬁcantly lower risk for future
type 2 diabetes compared with subjects
who require 60 min to return their
plasma glucose concentration back to the
fasting level (51) (Fig. 2).
ONE-HOUR PLASMA
GLUCOSE AND FUTURE
RISK OF TYPE 2 DIABETES —As
discussed earlier, models that include a
measure of -cell function would be ex-
pected to have a better predictor value for
the future risk of type 2 diabetes. Consis-
tentwiththis,wehaveshownthatthe1-h
plasma glucose concentration during the
OGTT correlates better than the 2-h
plasma glucose and FPG concentrations
withindicesofinsulinsecretionandinsu-
lin resistance (35,36) and with G0–120,
which is a strong predictor of future risk
for type 2 diabetes. Thus, the 1-h plasma
glucose should be a good predictor for
future risk of type 2 diabetes. To our sur-
prise, no previous epidemiological stud-
ies have assessed the predictive power of
the 1-h plasma glucose concentration for
future risk of type 2 diabetes. Moreover,
to the best of our knowledge, the only
large epidemiological studies to measure
the 1-h plasma glucose concentration at
baseline are the San Antonio Heart Study
(35)andtheBotniaStudy(36).IntheSan
Antonio Heart Study and the Botnia
Study, we measured the predictive power
of 1-h plasma glucose concentration us-
ing the area under the receiver-operating
curve (ROC) and compared the result to
Figure 2—Plasma glucose concentration during the OGTT in NGT subjects. Subjects were di-
vided into four groups (A) based on the time it takes to return their plasma glucose concentration
below the fasting level. B: The 8-year conversion rate to type 2 diabetes in the four groups of
subjects. See text for more details.
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plasma glucose concentrations. The area
under ROC for 1-h plasma glucose con-
centration is signiﬁcantly greater compared
with both the fasting and 2-h plasma glu-
cose concentrations (Fig. 3) and to a variety
of predictive models based only on mea-
surements taken during the fasting state
(Table1)(35,36).Furthermore,additionof
the 1-h plasma glucose concentration to
prediction models based on measurements
taken during the fasting state signiﬁcantly
strengthened their predictive power
(35,36).Acutoffpointof155mg/dlfor1-h
plasmaglucoseconcentrationstratiﬁessub-
jects into high- and low-risk groups, inde-
pendent of their glucose tolerance status
(36,52).Subjectswitha1-hplasmaglucose
155 mg/dl have high risk for future dia-
betes, whereas subjects with a 1-h plasma
glucose 155 mg/dl have low risk for fu-
ture type 2 diabetes.
SUMMARY— Models that identify
subjects at increased risk for future type 2
diabetes are essential for the development
effective prevention programs. Progressive
-cell failure is the principal factor respon-
sibleforthedevelopmentoftype2diabetes.
AlthoughsubjectswithIGTareatincreased
risk for future type 2 diabetes, the limita-
tions of IGT have provoked the search for
more effective predictive models. A variety
of multivariate models, based on measure-
ments taken during the fasting state, have
beendeveloped.Although,ingeneral,these
models are useful tools for identifying sub-
jects at increased risk for future type 2 dia-
betes, they correlate poorly with -cell
failure, the principal factor responsible for
the progressive deterioration of glucose tol-
erance, and subsequent development of
type 2 diabetes. The 1-h plasma glucose
concentration during the OGTT strongly
correlates with -cell function and, as ex-
pected, performs superiorly to other mod-
els/indexes in predicting the future risk for
type 2 diabetes. A 1-h cutoff point of 155
mg/dl during the OGTT stratiﬁes individu-
als into high and low risk for future devel-
opment of type 2 diabetes.
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